• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Virpax licenses Nanomerics’ MM2019 “molecular masking” nasal powder

Virpax Pharmaceuticals said that it has acquired exclusive North American rights to Nanomerics’ MMS019 nasal powder, which it calls a “high density molecular masking spray” and which is intended to block viruses from taking hold in the respiratory tract. Virpax said that MMS019 is in preclinical development for the prevention of COVID-19, seasonal flu, and other respiratory viruses and that the company “intends to develop this product for potential FDA accelerated review in healthy human volunteers as soon as possible.”

Earlier this year, Virpax said that it had completed a pre-IND meeting with the FDA regarding its intranasal enkephalin for the treatment of management of acute and chronic pain, which it also licensed from Nanomerics.

Virpax Chairman and CEO Anthony Mack said, “We believe MMS019 can work together with current personal protective equipment to enhance our ability to help prevent the spread of respiratory viral infections and seasonal influenza.”

Nanomerics Chief Scientific Officer Ijeoma Uchegbu commented, “We are pleased that Virpax has licensed MMS019 for the prevention of viral respiratory infections and that they will undertake the clinical development of MMS019 to potentially bring a new respiratory infection prophylactic product to the market.”

Read the Virpax Pharmaceuticals press release.

Share

published on August 25, 2020

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    © 2025 OINDPnews